Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens
This study has been completed.
Sponsor:
University of California, San Francisco
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01006005
First received: October 30, 2009
Last updated: November 20, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study is recruiting 50 patients initiating or switching to Atripla and comparing them to 250 individuals previously followed in a prospective study of HIV+ low income individuals recruited from homeless shelters, single room occupancy hotels and free meal food lines as part of the UCSF Reach Study. Adherence will be measured through monthly unannounced pill counts and electronic medication monitors.
| Condition |
|---|
|
HIV Infections Adherence |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
MedlinePlus related topics:
HIV/AIDS
Drug Information available for:
Atripla
U.S. FDA Resources
Further study details as provided by University of California, San Francisco:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
HIV infected, marginally housed
Criteria
Inclusion Criteria:
- 18+ years old;
- HIV+;
- Initiating Atripla within 6-months of recruitment;
- Lives in the Tenderloin, South of Market, or Mission District San Francisco;
- Capable of providing informed consent; and
- Willing to complete all study procedures.
Exclusion Criteria:
- Intoxication, cognitive dysfunction or psychosis will preclude potential subjects from informed consent.
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT01006005 History of Changes |
| Other Study ID Numbers: | IN-US-177-0106 |
| Study First Received: | October 30, 2009 |
| Last Updated: | November 20, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, San Francisco:
|
HIV Treatment experienced |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on May 21, 2013